Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

61.00 -0.23 (-0.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
Via Stocktwits
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction
Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events. 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.
Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo. 
Via Investor's Business Daily
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup
IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern. 
Via Chartmill
Earnings Scheduled For July 30, 2025
 
Via Benzinga
An Overview of Ionis Pharmaceuticals's Earnings
 
Via Benzinga
Earnings Scheduled For April 30, 2025
 
Via Benzinga
What's Going On With Takeda Stock On Friday?
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro. 
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock
 
Via Benzinga
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock
Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan. 
Via Benzinga
Ionis (IONS) Q2 Revenue Soars 101%
Via The Motley Fool
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Ionis (IONS) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug
Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations. 
Via Benzinga
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching
IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders. 
Via Chartmill
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know
 
Via Benzinga
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
Analyst Expectations For Ionis Pharmaceuticals's Future
 
Via Benzinga
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts
 
Via Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts
 
Via Benzinga
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products. 
Via Benzinga
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.